Hemostemix (CVE:HEM) Trading Up 27.9% – Time to Buy?

Hemostemix Inc. (CVE:HEM)’s share price rose 27.9% on Friday . The company traded as high as C$0.29 and last traded at C$0.28. Approximately 1,401,717 shares traded hands during mid-day trading, an increase of 100% from the average daily volume of 700,531 shares. The stock had previously closed at C$0.22.

Hemostemix Trading Up 27.9 %

The firm’s 50-day moving average price is C$0.10 and its 200-day moving average price is C$0.08. The stock has a market capitalization of C$23.96 million, a PE ratio of -13.75 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.